CIRM Funded Clinical Trials
Phase I Study of Chimeric Antigen Receptor Engineered T Cells targeting CD33 for the Treatment of Relapsed/Refractory Acute Myeloid Leukemia
Disease Area:
Leukemia, Acute Myeloid (AML)
Trial Sponsor:
Beckman Research Institute of City of Hope
Trial Stage:
Phase 1
Trial Status:
Launching
Targeted Enrollment:
N/A
